Literature DB >> 22661199

Interleukin-13-induced activation of signal transducer and activator of transcription 6 is mediated by an activation of Janus kinase 1 in cultured human bronchial smooth muscle cells.

Yoshihiko Chiba1, Kumiko Goto, Miwa Misawa.   

Abstract

BACKGROUND: The current study was carried out to identify the JAK molecule(s) that is involved in the IL-13-induced activation of STAT6 in cultured human bronchial smooth muscle cells (hBSMCs).
METHODS: Cultured hBSMCs were stimulated with IL-13 in the absence and presence of JAK inhibitor-I (a nonspecific JAKs inhibitor), tyrphostin-AG490 (a specific JAK2 inhibitor), WHI-P131 (a specific JAK3 inhibitor), or tyrphostin-AG9 (a specific Tyk2 inhibitor), and levels of phosphorylated STAT6 were measured by immunoblot analyses.
RESULTS: The IL-13-induced phosphorylation of STAT6 was abolished by JAK inhibitor-I, whereas the other inhibitors had no significant effect.
CONCLUSION: These findings indicate that the STAT6 phosphorylation/activation induced by IL-13 is mediated by an activation of JAK1 in cultured hBSMCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22661199     DOI: 10.1016/s1734-1140(12)70788-0

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  11 in total

Review 1.  Role of interleukin-13 in asthma.

Authors:  Jonathan Corren
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

Review 2.  Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13.

Authors:  Corrado Pelaia; Giulia Pelaia; Claudia Crimi; Angelantonio Maglio; Giuseppe Armentaro; Cecilia Calabrese; Angela Sciacqua; Luca Gallelli; Alessandro Vatrella
Journal:  Vaccines (Basel)       Date:  2022-06-19

3.  Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses.

Authors:  Shigeru Ashino; Katsuyuki Takeda; Hui Li; Vanessa Taylor; Anthony Joetham; Polly R Pine; Erwin W Gelfand
Journal:  J Allergy Clin Immunol       Date:  2013-12-22       Impact factor: 10.793

4.  Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks.

Authors:  Hanan M El-Laithy; Amal Youssef; Shereen S El-Husseney; Nesrine S El Sayed; Ahmed Maher
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

5.  IL-13 R110Q, a Naturally Occurring IL-13 Polymorphism, Confers Enhanced Functional Activity in Cultured Human Bronchial Smooth Muscle Cells.

Authors:  Ya-Fang He; Li Hua; Yi-Xiao Bao; Quan-Hua Liu; Yi Chu; Ding-Zhu Fang
Journal:  Allergy Asthma Immunol Res       Date:  2013-08-07       Impact factor: 5.764

6.  IL-13/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells.

Authors:  Hui Cao; Jing Zhang; Hong Liu; Ledong Wan; Honghe Zhang; Qiong Huang; Enping Xu; Maode Lai
Journal:  Oncotarget       Date:  2016-09-20

Review 7.  JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.

Authors:  Jacopo Angelini; Rossella Talotta; Rossana Roncato; Giulia Fornasier; Giorgia Barbiero; Lisa Dal Cin; Serena Brancati; Francesco Scaglione
Journal:  Biomolecules       Date:  2020-07-05

8.  Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study.

Authors:  Nozomi Tani; Nobutaka Kataoka; Yusuke Kunimatsu; Yusuke Tachibana; Takumi Sugimoto; Izumi Sato; Yuri Ogura; Kazuki Hirose; Takayuki Takeda
Journal:  Multidiscip Respir Med       Date:  2021-03-17

Review 9.  Dupilumab: a novel treatment for asthma.

Authors:  Alessandro Vatrella; Immacolata Fabozzi; Cecilia Calabrese; Rosario Maselli; Girolamo Pelaia
Journal:  J Asthma Allergy       Date:  2014-09-04

Review 10.  Dupilumab in the management of moderate-to-severe asthma: the data so far.

Authors:  Pilar Barranco; Elsa Phillips-Angles; Javier Dominguez-Ortega; Santiago Quirce
Journal:  Ther Clin Risk Manag       Date:  2017-09-01       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.